Q2 2026

EARNINGS PRESENTATION

August 5, 2026

Chemours™

Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the third quarter of 2026, the full year 2026 and the Company's corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the U.S. or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and our Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this presentation, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.

Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this presentation, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this presentation may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.

Second Quarter 2026 Highlights

Generated \$1.6B in Net Sales and \$247M in Adjusted EBITDA, supported by strong performance across all segments

Announced global TiO2 price increase effective June 1, 2026, as a continuation of December & April price actions; achieved a YTD TiO2 price increase of 5%

APM Performance Solutions net sales grew 8% YoY, underscoring momentum and mix shift towards high-value end markets for APM products

Free Cash Flows improved 128% YoY, with conversion of 46% and net leverage declining to 4.4x, advancing toward a long-term target of below 3x

Repaid €230 million of the outstanding tranche of the B-3 Euro-denominated Term Loan due August 2028 in the quarter

Second Quarter 2026 Financial Summary

($ in millions unless otherwise noted; excludes per share amounts)

	2Q26	2Q25	Y-o-Y Δ	1Q26	Q-o-Q Δ
Net Sales	**$1,591**	**$1,615**	**($24)**	**$1,381**	**$210**
Net (Loss) / Income[1]	($274)	($380)	$106	($29)	($245)
Adj. Net Income [2]	$64	$91	($27)	$8	$56
EPS [3]	**($1.81)**	**($2.53)**	**$0.72**	**($0.19)**	**($1.62)**
Adj. EPS [2,3]	**$0.42**	**$0.61**	**($0.56)**	**$0.05**	**$0.36**
Adj. EBITDA [2,4]	**$247**	**$260**	**($13)**	**$169**	**$78**
Operating Cash Flow	$158	$93	$65	($44)	$202
Capex	($44)	($43)	$1	($49)	$5
Free Cash Flow	**$114**	**$50**	**$64**	**($93)**	**$207**
FCF Conversion	46%	19%	27%	(55)%	101%

1 Net (Loss) / Income attributable to The Chemours Company.

2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items. Please refer to the attached "GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)" table.

3 Calculation based on diluted share count.

4 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. Please refer to the attached "GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)" table.

Adjusted EBITDA Bridge: 2Q26 versus 2Q25

($ in millions)



Price Impacts: $35 million due to higher pricing across the three primary segments, with strength in TiO_2 pricing tied to the three disclosed pricing actions since December of 2025.
Volume Impacts: ($33) million due to lower stationary AC aftermarket refrigerant sales of TSS Opteon™ blends in North America, compared with elevated demand in Q2 2025 driven by the initial aftermarket channel fill associated with stationary technology AC transition under the U.S. AIM Act, as well as lower volumes associated with the APM SPS Capstone™ line closure completed in the third quarter of 2025
Cost/Other: ($23) million primarily driven by inflationary pressures experienced across the portfolio, partially offset by global net cost reduction efforts.
Currency: $8 million primarily driven by favorable currency dynamics within the TT and TSS business units.

Quarterly Segment Summary

($ in millions unless otherwise noted)

Net Sales



Adjusted EBITDA and Margin (%)

31%	35%	36%	12%	7%	7%	13%	14%	8%

Liquidity Position as of June 30, 2026

($ in millions unless otherwise noted)

Total Liquidity [7]	$1.6B
Gross Debt	$3.9B
Net Debt [8]	$3.2B
TTM Net Leverage [9]	4.4x



[5] Total cash balances include $52 million and $53 million of restricted cash and restricted cash equivalents on Chemours' Balance Sheets as of June 30, 2026 and December 31, 2025, respectively. Restricted cash of $53 million at the end of the first quarter and $52 million at the end of the second quarter includes cash and cash equivalents held in escrow under the terms of the Memorandum of Understanding (MOU) related to potential future legacy liabilities.

[6] Cash to shareholders reflects approximately $15 million in dividends paid to shareholders during the second quarter of 2026.

[7] Total liquidity is calculated as the sum of $671 million unrestricted cash and cash equivalents and $953 million of revolving credit capacity, net of outstanding letters of credit. Restricted cash and restricted cash equivalents totaling $52 million is not included in this calculation. The Company announced an amendment and extension to its credit agreement in May 2025. The amended credit facility extends commitments to 2030 with a capacity of up to $1 billion until October 2026, comprised of $780 million maturing on May 2, 2030, and $220 million on October 7, 2026.

[8] Net Debt, which we also refer to herein as Total Debt Principal, Net, is calculated as gross debt less unrestricted cash and cash equivalents.

[9] TTM Net Leverage reflects Total Debt Principal, Net at quarter-end divided by trailing twelve months of Adjusted EBITDA.

STRATEGIC PROGRESS

PATHWAY TO THRIVE

Our Strategy

Chemours™

PATHWAY TO THRIVE

Operational Excellence	Enabling Growth	Portfolio Management	Strengthening the Long-Term
❑Manufacturing excellence as a basis for success ❑Improved and standardized operating model for consistent execution ❑Continuous improvement to adapt to changing markets	❑Investing smartly in selected growth projects ❑Commercial effectiveness to drive sales growth ❑Innovation and new product development	❑Holistic portfolio analysis focused on distinct value creation metrics ❑Shift product mix to higher value applications in growing end markets ❑Optimize asset footprint	❑Measurable progress on resolving legacy liabilities in the interest of stakeholders ❑Responsible manufacturing practices ❑Targeted policy efforts
>$250M cost reduction from 2024 to 2027	>5% Sales CAGR from 2024 to 2027	Driving shareholder value	Recognizing criticality of our chemistries

Balanced & Disciplined Capital Allocation To Create Shareholder Value

Expanding Free Cash Flow Conversion & Long-Term Objective of Net Leverage Below 3x Across Economic Cycles

Progress Achieved to Date

PATHWAY TO THRIVE

Operational Excellence	Enabling Growth	Portfolio Management	Strengthening the Long-Term
✓ Notable progress against the $250M of run-rate savings by end of 2027 across all areas of the company ✓ Advanced the Chemours Business System rollout, embedding Lean principles to drive continuous improvement in safety, quality, and reliability ✓ Executed a long-term chlorine supply agreement with Olin Corporation, supporting the long-term competitiveness of the DeLisle TiO2 site	✓ Recorded initial sales of less than $1 million for two-phase fluids during 2Q26 ✓ Continued sales in high-growth semiconductor and data center end markets contributing more than 40% of APM Performance Solutions sales ✓ Successful qualification of Chemours' two-phase immersion cooling fluid by Samsung Electronics and 2CRSi ✓ Implemented three global TiO2 pricing increases in the past 8 months, reflecting Chemours' value in reliability and quality	✓ Progressed APM European asset review, through the announced exit of the Villers-St. Paul site ✓ Exited SPS Capstone™ business to prioritize higher return businesses and strengthen Chemours' overall portfolio ✓ Closed a substantial tranche of the announced sale of the former Kuan Yin TiO2 site in April 2026 ✓ Shifted aspects of TT's mining operations to prioritize cash flow generation	✓ Reached a settlement with the EPA & WVDEP to resolve alleged permitting violations across three Chemours sites ✓ Agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve all environmental claims, including PFAS statewide ✓ Addressed nearly $2B of near-term debt maturities in the past 6 months ✓ Drove advocacy for the importance of Chemours' essential chemistry as a part of recent U.S. trade policy changes and evolving EU regulatory landscape

Balanced & Disciplined Capital Allocation: Received ~$287M initial net proceeds from the sale of the Kuan Yin site, positioning the Company to paydown €230M of outstanding debt, and helping to progress towards the long-term goal of below 3x net leverage

Established Participation Focused on AI Infrastructure

Data Center Use Cases



TSS' Opteon™ and Freon™ refrigerants serve today's data center installed base, while developing two-phase liquid cooling solutions support the next generation of data center infrastructure

Thermal Management

- Opteon™ and Freon™ refrigerants support current cooling infrastructure
- Insulation and coatings for temperature and humidity control

Performance Materials

- Teflon™ coatings for cable insulation, in-tool components, tank lining, and AF optical networking
- Krytox™ greases and oils for vacuum pumps and robotic systems
- Viton™ fluoroelastomers for component sealing

Specialty Fluid Transfer

- Teflon™ coatings for wafer etching fluid handling
- Teflon™ coatings for gas and liquid filtration

Semiconductor Fabrication Use Cases



APM Performance Solutions' Teflon™, Krytox™, and Viton™ satisfy critical needs in data centers and semiconductor fabs to extend service life, improve chip yields, and increase reliability

TSS / APM approximate a high-single-digit sales concentration in data center, semiconductor and advanced electronics, anticipated to experience robust growth in years ahead. More than 40% of APM's Performance Solutions sales are concentrated in these targeted markets.

Expanding Applications & R&D Priorities for AI Infrastructure

Two-Phase Direct to Chip



1. Liquid thermal management fluids circulate into the server rack manifold through a closed loop system
2. The manifold is connected to a specialized cold plate located directly on top of the chip which is used to cool down the chip, transferring heat to the fluid in the process
3. The fluid boils, exiting the cold plate as a vapor
4. The vapor returns to a Coolant Distribution Unit (CDU) to be condensed back to a liquid and recirculated back to the cold plate, repeating the closed loop

Two-Phase Immersion Cooling



1. Electronic equipment is submerged in Opteon™ 2P50 in a sealed container, allowing the fluid to directly contact the entire ecosystem, not just the chip
2. The heat from the electronic equipment causes the fluid to boil
3. Vapor rises and condenses back to a liquid when it makes contact with the condenser coil
4. The fluid returns to the pool in a passive cycle

Two-Phase Direct to Chip Differentiators

- ✓ *High thermal performance via direct phase change cooling*
- ✓ *Near zero water usage with closed loop direct-to-chip design*
- ✓ *Preserves standard server architecture by cooling high heat components directly*
- ✓ *Easy retrofits into existing data centers*

Two-Phase Immersion Cooling Differentiators

- ✓ *Near zero water usage with closed loop immersion design*
- ✓ *100% heat capture by cooling all IT components simultaneously*
- ✓ *Exceptional energy efficiency with zero fan and minimal mechanical cooling requirements*
- ✓ *Extended lifetime of the IT hardware equipment thanks to homogenous temperature*

Annual R&D investment of ~$20-25M focused on:

- ➢ Next-generation refrigerants to address evolving customer & regulatory needs
- ➢ Two-phase cooling technologies to enable next-generation chips, optimize total cost of ownership, and support AI scaling

Liquid Cooling & NGR additional areas of investment to continue to drive growth in data center cooling for years ahead.

Chemours™

Third Quarter

GUIDANCE

Third Quarter and Full Year 2026 Guidance

Sequential Business Outlook:

Third Quarter 2026 Outlook

- **Consolidated**
  - Net Sales: Expected to decrease in the (5%) to 0% range sequentially
  - Adjusted EBITDA: Expected to range between $175 million and $205 million
  - Corporate Expenses: Expected to range between $40 million and $45 million
  - Capital Expenditures: Expected to approximate $65 million
  - Free Cash Flow Conversion: Reflecting a source of cash of at least $50 million
- **TSS**
  - Net Sales: Expected to decrease in the mid-teens to twenty percentage range, driven by less favorable seasonality in connection with the 2026 cooling season in the Northern Hemisphere and weaker Opteon™ blends aftermarket refrigerant demand in North America elevated market inventory levels from the initial channel fill in mid-2025
  - Adjusted EBITDA: Expected to approximate $125 million to $140 million, primarily driven by the referenced less favorable seasonality.
- **TT**
  - Net Sales: Expected to increase in the low-to-mid single digits percentage range, driven by recent pricing announcements, with stable volumes
  - Adjusted EBITDA: Expected to range between $70 million and $80 million, driven by the referenced recent pricing actions.
- **APM**
  - Net Sales: Expected to increase in the mid-to-high single digits percentage range, driven by a return to normal operating levels at the Washington Works facility and continued strength in the Performance Solutions order book.
  - Adjusted EBITDA: Expected to be between $20 million and $30 million, driven by the referenced return to normal operations within APM's operational circuit and order book strength.

Full Year 2026 Outlook

Net Sales Growth	1 – 5%
Adjusted EBITDA	$775M - $825M
CapEx	$250M - $280M
Free Cash Flow Conversion	25%+

APPENDIX

TSS Segment Net Sales and Adjusted EBITDA (Unaudited)





Net Sales: The 1% year-over-year decrease was driven lower stationary AC aftermarket refrigerant sales of TSS Opteon™ blends in North America, compared with elevated demand in Q2 2025 driven by the initial aftermarket channel fill associated with stationary technology AC transition under the U.S. AIM Act, partially offset by higher Freon™ prices, primarily in automotive applications.

Adjusted EBITDA: The increase reflects the referenced pricing activity, aided by the timing of certain costs, in the quarter.

TT Segment Net Sales and Adjusted EBITDA (Unaudited)





Net Sales: The increase was driven by a 2% increase in global pricing and a 1% currency tailwind, more than offsetting a 2% decline in global volumes. Pricing increased across all regions, while the volume decline was driven by lower TiO2 sales across key end markets, with the exception of Asia excluding China and Latin America.

Adjusted EBITDA: The increase in Adjusted EBITDA was primarily driven by the referenced global pricing strength, partially offset by higher costs due to inflation.

APM Segment Net Sales and Adjusted EBITDA (Unaudited)

($ in millions)

% of total Net Sales



($ in millions)



Net Sales: The 6% decrease was primarily driven by a 9% decrease in volumes, partially offset by a 2% increase in price and a slight currency tailwind. The volume decline was primarily driven by the APM SPS Capstone™ line closure completed in the third quarter of 2025. Performance Solutions Net Sales increased 8% year-over-year, supported by order book strength and continued momentum in high-value specialty products serving data center and semiconductor end markets

Adjusted EBITDA: The decrease in Adjusted EBITDA was primarily driven by lower volumes due to the referenced product line exit and operational impacts related to the previously disclosed and resolved outage at the Washington Works site.

Segment Net Sales (Unaudited)

	2024				2025				2026	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Net sales by product group and segment										
Opteon™ refrigerants	$ 200	$ 227	$ 205	$ 178	$ 279	$ 375	$ 368	$ 243	$ 313	$ 337
Freon™ refrigerants	173	173	146	124	97	123	98	113	162	150
Foam, propellants, and other	81	119	117	88	90	99	94	88	93	104
Total Thermal & Specialized Solutions	454	519	468	390	466	597	560	444	568	591
Titanium Dioxide	562	643	642	598	575	629	591	534	541	639
Minerals & Other	30	33	30	34	22	28	21	27	18	22
Total Titanium Technologies	592	676	672	632	597	657	612	561	559	661
Advanced materials	190	212	214	191	178	214	190	172	143	184
Performance solutions	113	133	140	133	116	132	121	141	100	142
Total Advanced Performance Materials	303	345	354	324	294	346	311	312	243	326
Performance chemicals and intermediates	14	13	14	13	11	15	12	12	11	13
Total Other Segment	14	13	14	13	11	15	12	12	11	13
Total net sales	$ 1,363	$ 1,553	$ 1,508	$ 1,359	$ 1,368	$ 1,615	$ 1,495	$ 1,329	$ 1,381	$ 1,591

Segment Net Sales by Region (Unaudited)

	2024				2025				2026	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Net sales by geographic region										
North America:										
Thermal & Specialized Solutions	$ 271	$ 308	$ 256	$ 194	$ 233	$ 336	$ 316	$ 241	$ 326	$ 340
Titanium Technologies	246	274	270	236	267	282	252	221	235	267
Advanced Performance Materials	124	133	130	112	111	125	110	131	95	140
Other Segment	9	10	9	7	8	10	7	7	7	7
Total North America	650	725	665	549	619	753	685	599	663	754
Asia Pacific:										
Thermal & Specialized Solutions	39	53	55	53	53	59	69	53	71	72
Titanium Technologies	147	178	171	161	105	125	122	114	77	124
Advanced Performance Materials	105	127	138	148	115	147	138	132	89	117
Other Segment	3	2	3	3	2	3	3	3	2	4
Total Asia Pacific	294	360	367	365	275	334	332	301	239	317
Europe, the Middle East, and Africa:										
Thermal & Specialized Solutions	92	103	98	69	98	112	87	84	97	97
Titanium Technologies	124	130	126	131	142	156	141	128	151	156
Advanced Performance Materials	63	72	70	53	56	60	52	40	52	57
Other Segment	2	1	2	2	1	2	2	2	2	2
Total Europe, the Middle East, and Africa	281	306	296	255	297	330	282	254	302	312
Latin America (1):										
Thermal & Specialized Solutions	52	55	59	74	82	90	88	66	74	82
Titanium Technologies	74	95	105	104	83	94	97	99	96	114
Advanced Performance Materials	11	13	16	11	12	14	11	10	7	12
Other Segment	—	—	—	1	—	—	—	—	—	—
Total Latin America	137	163	180	190	177	198	196	175	177	208
Total net sales	$ 1,362	$ 1,554	$ 1,508	$ 1,359	$ 1,368	$ 1,615	$ 1,495	$ 1,329	$ 1,381	$ 1,591

[1] LATAM includes Mexico.

Segment Net Sales and Adjusted EBITDA (Unaudited)

	2024				2025				2026	2026
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Segment Net Sales										
Thermal & Specialized Solutions	$ 454	$ 519	$ 468	$ 390	$ 466	$ 597	$ 560	$ 444	$ 568	$ 591
Titanium Technologies	592	676	672	632	597	657	612	561	559	661
Advanced Performance Materials	303	345	354	324	294	346	311	312	243	326
Other Non-Reportable Segment	14	13	14	13	11	15	12	12	11	13
Total Company Net Sales	$ 1,363	$ 1,553	$ 1,508	$ 1,359	$ 1,368	$ 1,615	$ 1,495	$ 1,329	$ 1,381	$ 1,591
Segment Adjusted EBITDA										
Thermal & Specialized Solutions	$ 150	$ 160	$ 139	$ 122	$ 141	$ 207	$ 194	$ 128	$ 190	$ 213
Titanium Technologies	69	83	78	70	50	47	25	23	18	48
Advanced Performance Materials	30	45	38	47	32	50	14	12	5	26
Other Non-Reportable Segment	2	3	3	-	1	4	2	1	3	2
Corporate Expenses	(55)	(77)	(54)	(69)	(57)	(47)	(44)	(34)	(47)	(42)
Segment Adjusted EBITDA Margin										
Thermal & Specialized Solutions	33%	31%	30%	31%	30%	35%	35%	29%	33%	36%
Titanium Technologies	12%	12%	12%	11%	8%	7%	4%	4%	3%	7%
Advanced Performance Materials	10%	13%	11%	15%	11%	14%	5%	4%	2%	8%
Other Non-Reportable Segment	14%	23%	21%	0%	9%	27%	17%	10%	27%	15%

GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 1/2)

($ in millions except per share amounts)	Three Months Ended June 30, 2026		Three Months Ended June 30, 2025		Three Months Ended March 31, 2025		Twelve Months Ended June 30, 2026	Twelve Months Ended June 30, 2025
	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ amounts
(Loss) income before income taxes	$ (1)		$ (248)		$ (22)		$ (52)	$ (292)
Net (loss) income attributable to Chemours	$ (274)	$ (1.79)	$ (380)	$ (2.52)	$ (29)	$ (0.19)	$ (303)	$ (428)
Non-operating pension and other post-retirement benefit income	(3)	(0.02)	(2)	(0.01)	(2)	(0.01)	(12)	(5)
Exchange losses (gains), net	1	0.01	4	0.03	(1)	(0.01)	5	10
Restructuring, asset-related, and other charges	3	0.02	18	0.12	13	0.09	24	100
Goodwill impairment charge	—	—	—	—	—	—	—	56
Loss on extinguishment of debt	2	0.01	—	—	9	0.06	16	1
Gain on sales of assets and businesses, net	(266)	(1.74)	—	—	—	—	(273)	(1)
Transaction costs	—	—	2	0.01	2	0.01	6	4
Qualified spend recovery	(6)	(0.04)	(13)	(0.09)	(5)	(0.03)	(31)	(33)
Litigation-related charges	225	1	293	1.95	20	0.13	272	296
Environmental charges	144	0.94	60	0.40	7	0.05	184	75
Adjustments made to income taxes	207	1	179	1.19	1	0.01	209	191
Provision for (benefit from) income taxes relating to reconciling items	31	0	(70)	(0.47)	(7)	(0.05)	8	(81)
Adjusted Net Income	$ 64	$ 0.42	$ 91	$ 0.61	$ 8	$ 0.05	$ 105	$ 185
Net income attributable to non-controlling interests	—		1		—		(1)	1
Interest expense, net	68		67		69		273	268
Depreciation and amortization (11)	80		79		79		320	304
All remaining provision for income taxes	35		22		13		36	37
Adjusted EBITDA	$ 247		$ 260		$ 169		$ 733	$ 795

GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 2/2)

($ in millions except per share amounts)	Three Months Ended June 30, 2026 $ amounts	Three Months Ended June 30, 2026 $ per share*	Three Months Ended June 30, 2025 $ amounts	Three Months Ended June 30, 2025 $ per share*	Three Months Ended March 31, 2025 $ amounts	Three Months Ended March 31, 2025 $ per share*	Twelve Months Ended June 30, 2026 $ amounts	Twelve Months Ended June 30, 2025 $ amounts
Adjusted EBITDA	$ 247		$ 260		$ 169		$ 733	$ 795
Total debt principal							$ 3,914	$ 4,183
Less: Cash and cash equivalents							(671)	(502)
Total debt principal, net							$ 3,243	$ 3,681
Net Leverage Ratio (calculated using GAAP earnings)							-62.4x	(12.6)x
Net Leverage Ratio (calculated using Non-GAAP earnings)							4.4x	4.6x
Weighted-average number of common shares outstanding - basic	151,225,044		150,238,691		150,767,077			
Weighted-average number of common shares outstanding - diluted	152,813,557		150,506,761		151,586,805			
Basic (loss) earnings per share of common stock (2)	$ (1.81)		$ (2.53)		$ (0.19)			
Diluted (loss) earnings per share of common stock (1) (2)	$ (1.81)		$ (2.53)		$ (0.19)			
Adjusted basic earnings per share of common stock (2)	$ 0.42		$ 0.61		$ 0.05			
Adjusted diluted earnings per share of common stock (1) (2)	$ 0.42		$ 0.61		$ 0.05			

(1) In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended March 31, 2025 and December 31, 2024. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended March 31, 2025 and December 31, 2024 as Adjusted Net Income was in a net income position.

(2) Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers.

GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation

	Three Months Ended			Six Months Ended	
	June 30,		March 31,	June 30,	
	2026	2025	2026	2026	2025
Cash flows (used for) provided by operating activities	$ 158	$ 93	$ (44)	$ 114	$ (19)
Less: Purchases of property, plant, and equipment	(44)	(43)	(49)	(93)	(127)
Free Cash Flows	$ 114	$ 50	$ (93)	$ 21	$ (146)
Adjusted EBITDA	247	260	169	416	426
Free Cash Flow Conversion	46%	19%	(55)%	5%	(34)%

2026 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation; 2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free Cash Flow Conversion Reconciliation

	Estimated Year Ended December 31, 2026 Low	Estimated Year Ended December 31, 2026 High
Cash flows provided by operating activities	$ 445	$ 525
Less: Purchases of property, plant, and equipment	(250)	(280)
Free Cash Flows	$ 195	$ 245
Adjusted EBITDA	775	825
Free Cash Flow Conversion	25%	30%

(1) Cash flows provided by operating activities is inclusive of the anticipated $30 million cash taxes associated with the sale of the Kuan Yin site.

	(Estimated) Year Ending December 31, 2026 Low	(Estimated) Year Ending December 31, 2026 High
Net loss attributable to Chemours	$ (255)	$ (230)
Restructuring, transaction, and other costs, net (2)	375	375
Adjusted Net Income	120	145
Interest expense, net	270	280
Depreciation and amortization	320	320
All remaining provision for income taxes	65	80
Adjusted EBITDA	$ 775	$ 825

(1) The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.

(2) Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.